AdaptHealth's Turnaround Thesis Gets Its First Real Test Tuesday Morning

AdaptHealth Corp. (AHCO) reports first-quarter 2026 earnings before the market opens on May 5, 2026, with investors focused on whether the home healthcare provider can reverse a troubling pattern of earnings misses and deliver on its turnaround narrative. The company has missed analyst estimates in three of the past four quarters, including a significant 125% shortfall in Q2 2025, raising questions about operational execution and margin pressure in a business that should be benefiting from demographic tailwinds. With the stock trading near analyst price targets and technical momentum strengthening, this report will test whether management's restructuring efforts and new capitated contracts can finally translate into consistent profitability.

Part 1: Earnings Preview

AdaptHealth is a national leader in home healthcare solutions, operating across four segments: Sleep Health (CPAP and sleep therapy equipment), Respiratory Health (oxygen and ventilation equipment), Diabetes Health (continuous glucose monitors and insulin pumps), and Wellness at Home (durable medical equipment for post-acute care patients). The company serves approximately 4.3 million patients annually through 640 locations in 48 states, partnering with hospitals, sleep labs, and skilled nursing facilities.

For Q1 2026, analysts expect AdaptHealth to report an EPS loss of -$0.03, with estimates ranging from -$0.05 to -$0.01. The company most recently reported Q4 2025 EPS of $0.23, which missed the $0.30 consensus by 23.33%. Year-over-year, the Q1 2026 estimate represents a 50% decline from the -$0.02 loss reported in Q1 2025, reflecting continued near-term headwinds despite management's optimistic full-year guidance.

Three key themes define this earnings story:

Turnaround Execution and Margin Recovery: AdaptHealth has undergone significant restructuring, including leadership changes and operational improvements aimed at reversing margin compression. The company set patient census records across three segments in Q4 2025 and made strategic acquisitions, including a Hawaii-based HME provider to support a new capitated contract. Investors will scrutinize whether these initiatives are translating into improved profitability, particularly after the company provided 2026 guidance calling for full-year EPS of $0.79—a 102.56% increase from 2025's $0.39.

Consistency After Serial Misses: The earnings miss pattern is concerning: Q2 2025 saw a catastrophic 125% shortfall, followed by smaller misses in Q3 (-13.64%) and Q4 (-23.33%). While Q1 2025 met expectations, the subsequent three quarters suggest execution challenges or overly optimistic guidance. Analysts have lowered near-term estimates but remain constructive on the longer-term story, with the consensus expecting a sharp rebound to $0.15 EPS in Q2 2026 (a 600% year-over-year increase). This quarter will determine whether management has credibility to deliver on its projections.

Demographic Tailwinds vs. Reimbursement Pressure: AdaptHealth operates in markets with strong secular growth drivers—aging populations, rising diabetes prevalence, and the shift to home-based care. However, the company faces reimbursement headwinds from Medicare and commercial payors, which have pressured margins. The new capitated contract and geographic expansion into Hawaii represent strategic moves to diversify revenue streams, but investors need evidence that these efforts can offset pricing pressure and drive sustainable margin expansion.

Analyst commentary ahead of the release reflects cautious optimism. While the consensus maintains a Buy rating with a $13.19 price target (roughly in line with the current $13.04 price), recent downgrades from firms like Jefferies (Buy to Hold in January 2024) and BofA Securities (Neutral to Underperform in November 2023) highlight skepticism about near-term execution. The key question is whether AdaptHealth can demonstrate operational discipline and deliver results that justify the bullish full-year guidance, or whether another miss will erode confidence in management's turnaround plan.

Part 2: Historical Earnings Performance

AdaptHealth's recent earnings history reveals a troubling pattern of underperformance that has tested investor patience. Over the past four quarters, the company has missed analyst estimates three times, with only Q1 2025 meeting the -$0.02 consensus. The Q2 2025 report was particularly damaging: analysts expected $0.12 in earnings, but AdaptHealth delivered -$0.03, a 125% miss that sent the stock down sharply. Q3 2025 showed improvement with $0.19 in earnings (versus $0.22 expected, a 13.64% miss), and Q4 2025 came in at $0.23 (versus $0.30 expected, a 23.33% miss).

The pattern suggests persistent execution challenges rather than one-time issues. While the company has moved from losses to profitability in absolute terms—Q3 and Q4 2025 marked the first back-to-back profitable quarters in the dataset—the consistent shortfalls relative to expectations indicate either overly aggressive guidance from management or structural margin pressures that analysts have been slow to model. The magnitude of the Q2 2025 miss stands out as particularly concerning, suggesting a significant operational or reimbursement issue that quarter.

Looking at the trend, there is modest improvement: the miss percentages have narrowed from 125% in Q2 to 23.33% in Q4, and absolute earnings have turned positive. However, the Q1 2026 estimate of -$0.03 (a loss) suggests analysts expect near-term headwinds to persist before the anticipated rebound in Q2 2026. For this quarter, investors will be watching not just whether AdaptHealth can beat the low bar of -$0.03, but whether management can provide credible guidance that restores confidence in the full-year outlook.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

AdaptHealth typically reports earnings before the market opens, meaning Day 0 represents the first full trading session where investors react to results, and Day +1 captures follow-through momentum.

AdaptHealth's post-earnings price behavior shows significant volatility, with an average absolute Day 0 move of 13.38% and Day +1 follow-through averaging 4.85%. The stock has demonstrated a tendency for large initial reactions: the February 2026 report triggered a 13.95% decline, while the February 2025 report surged 24.44%, and the August 2024 report plunged 21.06%. This wide range reflects the market's uncertainty about the company's trajectory and its sensitivity to earnings surprises.

The direction of moves has been mixed, with no clear pattern of beats leading to gains or misses leading to losses. For example, the November 2025 report (which included a miss) still generated a 17.38% Day 0 gain, suggesting the market sometimes focuses more on forward guidance or operational commentary than the headline number. Conversely, the February 2026 miss led to a sharp 13.95% decline, indicating diminished patience after repeated disappointments.

Day +1 moves average 4.85%, suggesting that initial reactions often extend into the following session, though with less magnitude. The historical range data shows that intraday volatility is substantial, with Day 0 ranges averaging 12.74%, meaning the stock often swings dramatically between its high and low on earnings day before settling. Given the 11.08% expected move implied by options for the upcoming report, the market is pricing in volatility slightly below the historical average, but still anticipating a significant reaction. Investors should be prepared for a double-digit percentage swing in either direction depending on whether AdaptHealth can finally deliver a clean beat and credible guidance.

Part 2.2: Options Market Expected Move

The options market is pricing in an 11.08% expected move for AdaptHealth's upcoming earnings, slightly below the stock's historical average Day 0 move of 13.38% but well above the Day +1 average of 4.85%. This suggests options traders are anticipating significant volatility, though perhaps less extreme than some of the company's most dramatic post-earnings swings (such as the 24.44% surge in February 2025 or the 21.06% plunge in August 2024). The 11.08% implied move aligns more closely with recent reports like February 2026 (13.95%) and November 2025 (17.38%), indicating the market expects a meaningful reaction but is not pricing in a worst-case scenario.

Part 3: What Analysts Are Saying

Analysts maintain a constructive view on AdaptHealth despite recent execution challenges, with a consensus rating of 4.22 out of 5.00 (solidly in Buy territory) and an average price target of $13.19. The current breakdown shows 5 Strong Buy ratings, 1 Moderate Buy, and 3 Hold ratings, with no Sell or Strong Sell recommendations. This distribution reflects cautious optimism: while the majority of analysts see upside potential, the presence of three Hold ratings indicates some skepticism about near-term catalysts.

Analyst sentiment has remained unchanged over the past month, with ratings counts and the average recommendation holding steady at 4.22. This stability suggests analysts are taking a wait-and-see approach ahead of the Q1 report, neither upgrading in anticipation of a turnaround nor downgrading further after the recent string of misses. The lack of movement may also reflect that estimates have already been reset lower following the Q4 2025 disappointment, with the -$0.03 Q1 consensus representing a modest bar to clear.

The consensus price target of $13.19 implies virtually no upside from the current price of $13.04—just 1.2% potential appreciation. However, the range of targets is wide: the high estimate of $17.00 suggests 30.4% upside for bulls, while the low estimate of $9.50 implies 27.1% downside for bears. This dispersion reflects genuine uncertainty about AdaptHealth's trajectory: optimists see the demographic tailwinds, strategic initiatives, and full-year guidance as reasons to believe in a multi-quarter recovery, while skeptics point to the persistent earnings misses and reimbursement pressures as evidence that the turnaround will take longer than management projects. With the stock trading essentially at the consensus target, this earnings report becomes a critical inflection point—a beat and raised guidance could drive the stock toward the high-end targets, while another miss could push it toward the low end of the range.

Part 4: Technical Picture

AdaptHealth enters earnings with strong technical momentum, as the Barchart Technical Opinion currently shows a 100% Buy signal, unchanged from both one week ago and one month ago. This consistent bullish reading indicates sustained positive momentum heading into the report, with the stock demonstrating resilience despite the challenging earnings history.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates near-term momentum is decisively positive, suggesting traders are positioning bullishly ahead of earnings
• Medium-term (100% Buy): Continued strength in the intermediate timeframe reflects confidence in the multi-quarter recovery narrative
• Long-term (100% Buy): The long-term buy signal suggests the broader trend remains constructive despite recent operational challenges

Trend Characteristics: The technical setup ranks in the Top 1% of all stocks with a Strengthening direction, indicating AdaptHealth is exhibiting exceptional relative strength and building positive momentum at a critical juncture.

The moving average structure reinforces the bullish technical picture: AHCO is trading above its 10-day ($12.93), 20-day ($12.67), 50-day ($11.27), 100-day ($10.76), and 200-day ($10.03) moving averages, though it sits slightly below the 5-day average ($13.16), suggesting a minor near-term pullback within an otherwise upward trend. The stock has gained approximately 30% from its 200-day average, reflecting a sustained rally that has carried it into earnings.

Key technical levels to watch include the 5-day moving average at $13.16 as immediate resistance and the 10-day average at $12.93 as near-term support. The stock's position above all major moving averages from 10-day through 200-day provides a cushion of technical support, with the rising 20-day average at $12.67 representing a logical first line of defense if the earnings reaction is negative. Conversely, a break above $13.16 on a positive report could open the door to a test of the high-end analyst price target at $17.00. The overall technical setup is supportive heading into earnings, with momentum indicators and trend strength suggesting the path of least resistance remains higher—but the 11.08% expected move means a disappointing report could quickly erase recent gains and test the 20-day or even 50-day moving averages. The strengthening trend and top-percentile ranking indicate the stock has built a technical foundation that could amplify gains on a positive surprise, but the proximity to the consensus price target suggests much of the near-term optimism may already be reflected in the current price.